Scarica l'app Stockscreener
9.52
22.73%
-2.80
Precedente Chiudi:
$12.32
Aprire:
$9.145
Volume 24 ore:
25.34M
Relative Volume:
3.40
Capitalizzazione di mercato:
$1.02B
Reddito:
$52.86M
Utile/perdita netta:
$-480.19M
Rapporto P/E:
-2.0299
EPS:
-4.6899
Flusso di cassa netto:
$-421.82M
1 W Prestazione:
-24.56%
1M Prestazione:
-53.42%
6M Prestazione:
+30.59%
1 anno Prestazione:
-40.50%
Intervallo 1D:
$8.96
$10.11
Intervallo di 1 settimana:
$8.96
$13.69
Portata 52W:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.52 | 1.32B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
NTLA: Analyst Chardan Capital Lowers Price Target; Maintains Buy Rating | NTLA Stock News - GuruFocus
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Wells Fargo Lowers PT on Intellia Therapeutics (NTLA), Maintains Rating | NTLA Stock News - GuruFocus
NTLA: RBC Capital Maintains Rating, Lowers Price Target by 36% | - GuruFocus
Intellia Therapeutics patient death prompts FDA clinical hold on CRISPR heart disease trials - The Business Journals
RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating - MarketScreener
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial - Genetic Engineering and Biotechnology News
Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers - BioPharma Dive
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year - TipRanks
Intellia Therapeutics Says a Patient Died in Gene Editing Trial - Barron's
Wedbush Maintains NTLA Rating, Lowers Price Target to $7 | NTLA Stock News - GuruFocus
NTLA’s Trials Pause: A Trigger for Stock Decline? - StocksToTrade
Intellia Tumbles After Patient Dies Following Crispr Treatment - Bloomberg.com
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - TradingView
Intellia Therapeutics stock price target lowered to $9 at RBC after patient death - Investing.com Canada
NTLA's Analyst Rating Maintained but Price Target Lowered | NTLA Stock News - GuruFocus
Patient with liver damage in Intellia trial dies - statnews.com
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Reports Strong Revenue Growth and S - GuruFocus
Is It Too Late to Buy NTLA? - timothysykes.com
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - AOL.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Intellia shares fall after hospitalised CRISPR patient dies - pharmaphorum
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate - BioSpace
Intellia Therapeutics (NTLA) Shares Plunge After Phase 3 Trial S - GuruFocus
JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12 - MarketScreener
JP Morgan Downgrades Intellia Therapeutics (NTLA) with Lower Pri - GuruFocus
Intellia stock plunges after patient death (NTLA:NASDAQ) - Seeking Alpha
Chart overlay techniques for tracking Intellia Therapeutics Inc.Forecast Cut & High Win Rate Trade Alerts - newser.com
Patient hospitalised after receiving Intellia's CRISPR therapy dies - FirstWord Pharma
Intellia Therapeutics (NTLA) Faces Setback with FDA Hold on Key Trials - GuruFocus
Intellia Therapeutics stock rating maintained at Neutral by Baird - Investing.com India
Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty - TipRanks
Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan - TipRanks
Transcript : Intellia Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Patient dies after receiving Intellia's CRISPR therapy - Fierce Biotech
JPMorgan downgrades Intellia Therapeutics stock on liver toxicity concerns - Investing.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Earnings Summary & Precise Buy Zone Identification - newser.com
Intellia Trims Losses And Edges Toward Major Drug Launch - Finimize
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury - Endpoints News
Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback - TipRanks
Intellia Therapeutics Third Quarter 2025 Financial Results Call - Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Intellia Therapeutics Q3 2025 Earnings: EPS of -$0.99 and Revenue of $15.19 Million Meet Estimates - GuruFocus
Intellia Therapeutics Inc earnings beat by $0.09, revenue fell short of estimates - Investing.com
Intellia Q3 net loss narrows - MarketScreener
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics
Intellia (NASDAQ: NTLA) completes HAELO Phase 3 enrollment; topline mid-2026 - Stock Titan
Will Intellia Therapeutics Inc. (38I) stock recover faster than industry2025 Volatility Report & AI Powered Market Trend Analysis - newser.com
Does Intellia Therapeutics Inc. stock trade at a discount to peersWeekly Trade Summary & High Accuracy Investment Signals - fcp.pa.gov.br
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.44%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):